Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 6Active not recruiting 3Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Mantle-Cell 4Lymphoma 3Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Mature B-Cell Malignancies 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Hematologic Neoplasms 1Hematologic Diseases 1B-cell Malignancies 1

Interventions

Cyclophosphamide 26Rituximab 22Biopsy 17Specimen Handling 16Prednisone 15Magnetic Resonance Spectroscopy 14Doxorubicin 14fludarabine 12Vincristine 12fludarabine phosphate 9Etoposide 7Bendamustine Hydrochloride 7Tacrolimus 6Nuclear Medicine Department, Hospital 6Melphalan 6trametinib 5acalabrutinib 5X-Rays 5Whole-Body Irradiation 5Radiotherapy 5Mycophenolic Acid 5Lenalidomide 5Crizotinib 5pembrolizumab 4ibrutinib 4copanlisib 4Prednisolone 4Mesna 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma × zanubrutinib × Clear all
NCT04662255 2026-05-15

BRUIN-MCL-321

Eli Lilly and Company

Phase 3 Active not recruiting
500 enrolled
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06067048 2026-03-06

HOVON169CAD

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 2 Active not recruiting
25 enrolled
Lymphoid

Lymphoma

NCT05952037 2026-01-02

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

BeOne Medicines

Phase 2 Active not recruiting
114 enrolled
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡